Clinical trials: HiV1- Positive
HIV Positive, Herpes Simplex, Genital
Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes
To determine the efficacy of Famvir 500mg bd as suppressive antiviral therapy for acute genital Herpes simplex virus (HSV) outbreaks in HIV subjects.
- Trial name
- NCT01154543
- Volunteers
- 42 people
- Sponsor
- Holdsworth House Medical Practice
HIV Infections
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period that immediately follows infection with…
- Trial name
- NCT00006441
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 398 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections are leading causes of early death in patients who initiate antiretroviral therapy (ART) with advanced immunodeficiency.
- Trial name
- STATIS (NCT02057796)
- Testing
- Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, ART (Atripla, Truvada, Efavirenz, Combivir), Rifampin, isoniazid, pyrazinamide, ethambutol
- Where
- 4 sites in Cambodia, Côte d’Ivoire and 2 more
- Volunteers
- 1,050 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
HIV-1 Infection
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks.
- Trial name
- WIP (NCT01213316)
- Testing
- Raltegravir
- Volunteers
- 451 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
Study Design: This is a Phase I, randomized, placebo-controlled, double-blinded study to examine safety, tolerability and immune response of a prime-boost vaccination regimen for treatment of HIV infection.
- Trial name
- NCT00270465
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01797445
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Canada and 9 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences
Tuberculosis, Hiv
A One-stop Shop for the Same Day Diagnosis and Management of TB and HIV
TB is a major public health problem and the second most common cause of adult death due to infection in many low-income countries.
- Trial name
- NCT04043390
- Testing
- CRP and Molbio Truenat MTB, CRP and Xpert ULTRA MTB/RIF, standard test Xpert
- Where
- Nigeria
- Volunteers
- 1,100 people
- Sponsor
- Liverpool School of Tropical Medicine
HIV-1 Infection, Tuberculosis
PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
This study was done to evaluate the effect of HIV and TB treatment on a commonly used birth control method. It enrolled women who were infected with HIV and TB and were taking efavirenz (EFV; Sustiva®; an anti-HIV medication)…
- Trial name
- PRIDE-HT (NCT02412436)
- Testing
- Depot medroxyprogesterone acetate
- Where
- 5 sites in Botswana, Kenya and 2 more
- Volunteers
- 62 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
This study (POLAR), is designed to assess the antiviral activity and safety of CAB LA plus RPV LA, administered Q2M, in approximately 100 adult HIV-1 infected, antiretroviral therapy (ART) experienced participants.
- Trial name
- NCT03639311
- Testing
- CAB LA, RPV LA, RPV
- Where
- 30 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
The purpose of this study is to examine how the level of HIV is reduced in the blood when anti-HIV therapy is initiated. This study will also evaluate whether adding GM-CSF or IL-12 to the anti-HIV drug regimen will increase the…
- Trial name
- NCT00000896
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
To evaluate the safety of HIV-1 gp120 C4-V3 hybrid polyvalent peptide immunogen (C4-V3 peptides) formulated in mineral oil containing mannose mono-oleate (IFA) in HIV-1 uninfected volunteers.
- Trial name
- NCT00000886
- Testing
- HIV-1 C4-V3 Polyvalent Peptide Vaccine
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Gene Transfer for HIV Using Autologous T Cells
This is a pilot study to determine the safety and feasibility of lentivirus-transduced T-cell immunotherapy in patients who have failed highly active anti-retrovirus therapy (HAART).
- Trial name
- Gene Transfer (NCT01153646)
- Testing
- pHIV7-shI-TAR-CCR5RZ treated CD4 cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
HIV Infections
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor.
- Trial name
- NCT00051831
- Testing
- Emtricitabine, Enfuvirtide, Ritonavir
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
The purpose of this study is to see how HIV-positive patients who are taking anti-HIV drugs and have a viral load (level of HIV in the blood) of 1,500 copies/ml or more respond to GM-CSF (granulocyte-macrophage colony-stimulating…
- Trial name
- NCT00000850
- Testing
- Indinavir sulfate, Sargramostim
- Where
- 39 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Improving HIV-1 Control in Africa With Long Acting Antiretrovirals
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care.
- Trial name
- IMPALA (NCT05546242)
- Testing
- Cabotegravir/Rilpivirine, Antiretroviral
- Where
- 7 sites in Kenya, South Africa and 1 more
- Volunteers
- 540 people
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
HIV I Infection, HIV Associated Lipodystrophy
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue.
- Conditions
- HIV I Infection, HIV Associated Lipodystrophy, Metabolic Syndrome, Aging
- Trial name
- NCT04887675
- Testing
- MRI
- Where
- Serbia
- Volunteers
- 120 people
- Sponsor
- University of Novi Sad
HIV Positive
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects
Co-morbidities, including low bone mineral density, increased visceral adiposity and chronic kidney disease (CKD) are frequent in people living with HIV, and may be driven by ongoing inflammation and immune activation.
- Trial name
- BIGGER (NCT03660722)
- Testing
- blood and urinary samples
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
HIV/AIDS, Tuberculosis, Pulmonary
INSTI's For The Management of HIV-associated TB
This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected…
- Trial name
- INSIGHT (NCT04734652)
- Testing
- Biktarvy®, TLD- fixed-drug combination single tablet
- Where
- South Africa
- Volunteers
- 122 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV Infections
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632.
- Trial name
- NCT00004584
- Testing
- Atazanavir, Ritonavir, Saquinavir
- Where
- 38 sites in United States, Canada and 3 more
- Sponsor
- Bristol-Myers Squibb